Gastrointestinal phenotype of fabry disease in a patient with pseudoobstruction syndrome

JIMD Reports

Volumn 4, Issue , 2012, Pages 25-28

  Buda, Piotr ^a   Wieteska Klimczak, Anna ^a   Ksiazyk, Janusz ^a   Gietka, Piotr ^b   Smorczewska Kiljan, Anna ^a   Pronicki, Maciej ^a   Czartoryska, Barbara ^c   Tylki Szymanska, Anna ^a  

^a CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^b INSTITUTE OF RHEUMATOLOGY   (Poland)

^c INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

Collagenous colitis; Colonic pseudoobstruction; Cutaneous vascular lesion; Fabry disease; Sweat gland function

Indexed keywords

EID: 84884222125     PISSN: 21928304     EISSN: 21928312     Source Type: Book Series    
DOI: 10.1007/8904_2011_63     Document Type: Chapter

References (15)

1. Aerts JM, Groener JE, Kuiper S, Donker-Koopman SA, Ottenhoff R, Roomen C, Mirzaian M, Wijburg FA, Linthorst GE, Vedder AC, Rombach SM, Cox-Brinkman J, Somerharju P, Boot RG, Hollak CE, Brady RO, Poorthuis BJ (2008) Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA 105(8):2812–2817
2. Argoff CE, Barton NW, Brady RO, Ziessman HA (1998) Gastrointestinal symptoms and delayed gastric emptying in Fabry’s disease: response to metoclopramide. Nucl Med Commun 19:887–891
3. Breunig F, Weidemann F, Strotmann J, Knoll A, Wanner C (2006) Clinical benefit of enzyme replacement therapy in Fabry disease. 2006. Kidney Int 69:1216–1221
4. Bryan A, Knauft RF, Burns WA (1977) Small bowel perforation in Fabry’s disease. Ann Intern Med 86:315–316
5. Desnick R, Ioannou Y, Eng C (2001) Alpha-galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 3733–3774
6. Hilz MJ (2002) Evaluation of peripheral and autonomic nerve function in Fabry disease. Acta Paediatr Suppl 91:38–42
7. Hoffmann B, Schwarz M, Mehta A, Keshav S (2007) Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Clin Gastroenterol Hepatol 5:1447–1453
8. Jardine DL, Fitzpatrick MA, Troughton WD, Tie AB (1994) Small bowel ischaemia in Fabry’s disease. J Gastroenterol Hepatol 9:201–204
9. Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999) Prevalence of lysosomal storage disorders. JAMA 281:249–254
10. O’Brien BD, Shnitka TK, McDougall R, Walker K, Costopoulos L, Lentle B, Anholt L, Freeman H, Thomson AB (1982) Pathophysiologic and ultrastructural basis for intestinal symptoms in Fabry’s disease. Gastroenterology 82:957–962
11. Schiffmann R, Warnock D, Banikazemi M, Bultas J, Linthorst G, Packman S, Sorensen S, Wilcox W, Desnick R (2009) Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 24:2102–2111
12. Sheth KJ, Werlin SL, Freeman ME, Hodach AE (1981) Gastrointestinal structure and function in Fabry’s disease. Am J Gastroenterol 76:246–251
13. Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ (2006) High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 79:31–40
14. Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P (2009) Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med 11:790–796
15. Zarate YA, Hopkin RJ (2008) Fabry’s disease. Lancet 372:1427–1435